On March 18, WuXi AppTec executives talked about the application of AI in the pharmaceutical industry in the 2024 earnings call and said that the pharmaceutical industry, especially in the R&D stage, is exploring how to use AI to accelerate the development of innovative drugs. This is in a relatively early stage, and we also have services to empower many such customers. We believe that AI, as an innovative tool, can help the entire industry improve efficiency and speed, and may help new drug development open up more previously undrugable spaces in the future. We will also follow the trend and better provide customers with the ultimate service. WuXi AppTec executives also emphasized that there is a lot of information about AI on the Internet, especially about AI new drugs, but it should be made clear that WuXi AppTec has never developed new drugs on its own, nor has it used AI to develop new drugs. Including recent news on the Internet that WuXi AppTec uses Chemistry42 to develop AI new drugs. We also want to clarify that the technology mentioned here is from a biotech company and has nothing to do with WuXi AppTec. As an integrated CRDMO service platform, we have always been doing a good job of enabling services, which will bring us more customers and business opportunities.